New Hope Against Diseases Marked by Progressive Scarring of Lung Tissue
The Pharma Data
JANUARY 15, 2021
Right now, no medication is approved specifically for pulmonary hypertension caused by ILD, said Dr. Steven Nathan, senior researcher on the new trial. Food and Drug Administration to approve Tyvaso for ILD patients. The trial, funded by Tyvaso maker United Therapeutics, involved 326 patients.
52 
Let's personalize your content